Masatoshi Kudo
工藤正俊
MD, PhD
Professor and Chairman, Department of Gastroenterology and Hepatology消化内科暨肝脏病科主任教授
👥Biography 个人简介
Masatoshi Kudo is Japan's foremost HCC authority, contributing pivotal research on lenvatinib, TACE combined with systemic therapy, and HCC staging in Asian populations. He is editor-in-chief of Liver Cancer and a leading voice in Asia-Pacific HCC guideline development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lenvatinib in HCC
Played a central role in the REFLECT trial and pioneered investigation of lenvatinib's activity in Japanese HCC patients, driving regulatory approval in Japan.
TACE Plus Systemic Therapy
Led research into combining TACE with systemic agents (TACE plus lenvatinib/sorafenib), advancing treatment for intermediate-stage HCC.
HCC Staging in Japan
Developed and refined the Japanese HCC staging systems and treatment algorithms widely adopted across Asia-Pacific oncology centers.
Representative Works 代表性著作
Lenvatinib versus sorafenib in first-line treatment of HCC (REFLECT)
The Lancet (2018)
Co-authored pivotal non-inferiority trial establishing lenvatinib as a new first-line option for advanced HCC.
TACE combined with lenvatinib for intermediate-stage HCC
Journal of Hepatology (2020)
Phase II trial supporting the efficacy and safety of TACE plus lenvatinib, paving the way for combination phase III studies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 工藤正俊 的研究动态
Follow Masatoshi Kudo's research updates
留下邮箱，当我们发布与 Masatoshi Kudo（Kindai University Faculty of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment